Literature DB >> 28013489

RSK2 and its binding partners in cell proliferation, transformation and cancer development.

Yong-Yeon Cho1.   

Abstract

RSK2 is a serine/threonine kinase and a member of the p90 ribosomal S6 kinase (p90RSK; RSKs) family, which regulates cell proliferation and transformation induced by tumor promoters such as epithelial growth factor (EGF), 12-O-tetradecanoylphorbol-13-acetate (TPA), and ultraviolet (UV) radiation. RSKs respond to many growth factors, hormones, neurotransmitters and environmental stresses. In signaling cascades, RSK2 is regulated under the control of extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) activities and is positioned upstream of transcription and epigenetic factors involved in cell proliferation, cell transformation and cancer development, as well as some kinases that modulate cell cycle progression. Over the last decade, our research group has studied the etiological roles of RSK2 in human cancer development, discovering that RSK2 plays a key role in cell proliferation, transformation and cancer development in humans. Based on our research, we concluded that RSK2 plays a key role as an onco-kinase by combinational protein-protein interaction with different binding partners depending on the cellular context. In this review, we discuss the function of the RSK2 signaling axis by interactions with binding partners in cancer development.

Entities:  

Keywords:  Cell proliferation; Cell transformation; Protein–protein interaction; RSK2; Signaling axis

Mesh:

Substances:

Year:  2016        PMID: 28013489     DOI: 10.1007/s12272-016-0880-z

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  5 in total

1.  Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.

Authors:  Juhee Park; Ga-Eun Lee; Hyung-Jung An; Cheol-Jung Lee; Eun Suh Cho; Han Chang Kang; Joo Young Lee; Hye Suk Lee; Jin-Sung Choi; Dae Joon Kim; Jong-Soon Choi; Yong-Yeon Cho
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

Review 2.  Animal Models for Coffin-Lowry Syndrome: RSK2 and Nervous System Dysfunction.

Authors:  Matthias Fischer; Thomas Raabe
Journal:  Front Behav Neurosci       Date:  2018-05-23       Impact factor: 3.558

3.  Identification of p90 Ribosomal S6 Kinase 2 as a Novel Host Protein in HBx Augmenting HBV Replication by iTRAQ-Based Quantitative Comparative Proteomics.

Authors:  Li-Bo Yan; You-Jia Yu; Qing-Bo Zhang; Xiao-Qiong Tang; Lang Bai; FeiJun Huang; Hong Tang
Journal:  Proteomics Clin Appl       Date:  2018-02-06       Impact factor: 3.494

4.  Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells.

Authors:  Ji-Hong Song; Cheol-Jung Lee; Hyun-Jung An; Sun-Mi Yoo; Han C Kang; Joo Y Lee; Kwang D Kim; Dae J Kim; Hye S Lee; Yong-Yeon Cho
Journal:  Mol Carcinog       Date:  2018-09-21       Impact factor: 4.784

5.  Osteoblast-specific inactivation of p53 results in locally increased bone formation.

Authors:  Nannan Liao; Till Koehne; Jan Tuckermann; Ioanna Triviai; Michael Amling; Jean-Pierre David; Thorsten Schinke; Julia Luther
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.